FDA Approves CAPVAXIVE For Prevention Of Invasive Pneumococcal Disease And Pneumococcal Pneumonia In Adults
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved CAPVAXIVE (V116) for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults. The vaccine covers serotypes responsible for approximately 84% of such diseases in adults aged 50 and older. Four Phase 3 studies showed robust immune responses in both vaccine-naïve and vaccine-experienced adults.
June 17, 2024 | 9:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck (MRK) received FDA approval for its vaccine CAPVAXIVE (V116), which targets invasive pneumococcal disease and pneumonia in adults. This approval could boost Merck's revenue and market position in the vaccine segment.
The FDA approval of CAPVAXIVE (V116) is a significant milestone for Merck, as it addresses a major health concern in adults aged 50 and older. The robust immune responses demonstrated in Phase 3 studies further validate the vaccine's efficacy, likely leading to increased adoption and sales. This approval strengthens Merck's position in the vaccine market, potentially driving revenue growth.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100